Sanxiang Metropolis Daily·New Hunan Client August 14th (All media reporter Li Qi, intern Sun Xin, Yang Yisha, correspondent Zhang Ying) Recently, a piece of good news that will benefit psoriasis patients came: human stem cells The National Engineering Research Center provides stem cell preparations, and the Phase 1/2a clinical research project on "human umbilical cord-derived mesenchymal stem cells for the treatment of psoriasis" conducted at Xiangya Hospital of Central South University has been completed.
html On August 5, the research results were published online in the form of a clinical research article in the authoritative international academic journal "Signal Transduction and Targeted Therapy" (impact factor 38.104), evaluating the safety and effectiveness of human umbilical cord-derived mesenchymal stem cells in the treatment of psoriasis. Effectiveness, and preliminary exploration of the possible mechanism of action, represents a major breakthrough in the clinical research field of stem cell treatment of psoriasis in my country.
(Screenshot of this clinical research paper)
Professor Lu Guangxiu, director of the National Engineering Research Center for Human Stem Cells and a well-known expert on reproductive and stem cells in my country, introduced that this research is the first time in the world to publish "the use of human umbilical cord-derived mesenchymal stem cells (UMSCs)" ) Phase 1/2a single-arm clinical trial results for the treatment of psoriasis (registered clinical registration number NCT03765957). The study found that allogeneic UMSCs transplantation is safe and partially effective in patients with psoriasis, with an effective rate of 25% for men and 66.7% for women. Women are more effective than men; lower levels of Treg cells before treatment predict Better treatment response may be a predictive factor for UMSCs to effectively treat psoriasis. According to experts from the
project team, psoriasis (commonly known as "psoriasis") is a common chronic, relapsing, inflammatory, and systemic disease that currently affects about 125 million people around the world. It is the disease with the longest course and the most serious impact on the quality of life. The immune-related skin disease with the greatest impact has no cure. Although major breakthroughs have been made in the field of psoriasis with targeted biologics and small molecule drugs, the triggering factors of the disease remain unclear. Once biologic agents are discontinued, the disease often relapses. The immunomodulatory ability of mesenchymal stem cells (MSCs) makes them a promising new therapeutic method for the clinical treatment of immune-related diseases. Previously, case reports on stem cell treatment of psoriasis have been released internationally, but there is a lack of systematic and in-depth clinical research.
Reporters learned that the clinical study on "Human Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Psoriasis" was jointly filed by the Department of Dermatology, Xiangya Hospital of Central South University and the National Engineering Research Center for Human Stem Cells (Hunan Guangxiu High-tech Life Technology Co., Ltd.) in May 2018. Obtained and registration by the National Health and Medical Commission. It is one of the three clinical studies of stem cell treatment for psoriasis nationwide. The first subject was treated in March 2019. It is the first stem cell treatment for diseases in Hunan Province. clinical research. The umbilical cord mesenchymal stem cell preparation used in the
project comes from the National Engineering Research Center for Human Stem Cells in Changsha, Hunan. The center has a cell preparation center built in accordance with EU and Chinese GMP standards, has established a large-scale cell preparation platform, and has a stem cell foundation. Technical teams for research, translational research, production and quality inspection. The relevant cell preparations have passed the quality review of the China Institute of Food and Drug Control and the safety test of the Guangdong Medical Experimental Animal Center, fully confirming that umbilical cord mesenchymal stem cells have reached the quality standards for clinical application.
[Editor: Chen Shuyi]
[Source: Sanxiang Metropolis Daily]
